Trial Profile
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs TPIV 200 (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 03 Jul 2023 Planned End Date changed from 15 Dec 2023 to 1 Jun 2024.
- 02 Feb 2023 Planned End Date changed from 15 Dec 2022 to 15 Dec 2023.
- 06 Oct 2021 Planned End Date changed from 15 Dec 2021 to 15 Dec 2022.